Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study

Emberton M, Fitzpatrick JM, Garcia-Losa M et al (2008) Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU Int 102:981–986

Peters TJ, Donovan JL, Kay HE et al (1997) The International Continence Society “benign prostatic hyperplasia” study: the bothersomeness of urinary symptoms. J Urol 157:885–889

Lemack GE (2007) Defining the role of overactive bladder treatments in men with lower urinary tract symptoms. Nat Clin Pract Urol 4:174–175

Chapple CR, Khullar V, Gabriel Z et al (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54:543–562

Kaplan SA, Walmsley K, Te AE et al. (2005) Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174: 2273–2275 discussion 2275–2276

Chung BH, Hong SJ, Cho JS et al (2006) Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study. BJU Int 97:742–746

Lee E, Yoo KY, Kim Y et al (1998) Prevalence of lower urinary tract symptoms in Korean men in a community-based study. Eur Urol 33:17–21

Blaivas JG, Panagopoulos G, Weiss JP et al (2007) Validation of the overactive bladder symptom score. J Urol 178:543

Coyne KS, Matza LS, Kopp Z et al (2006) The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 49:1079–1086

Takei M, Homma Y, Japanese Tolterodine Study Group (2005) Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. Int J Urol 12:456–464

Roehrborn CG, Kaplan SA, Kraus SR et al (2008) Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology 72: 1061–1067 discussion 1067

Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50: 1306–1314 discussion 1314–1315

Kaplan SA, Roehrborn CG, Rovner ES et al (2006) Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296:2319–2328

Kaplan SA, He W, Koltun WD et al (2012) Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. Eur Urol 63:158–165

Abrams P, Kaplan S, De Koning Gans HJ et al (2006) Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175: 999–1004

Abrams P, Speakman M, Stott M et al (1997) A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 80:587–596

Sun YH, Liu ZY, Zhang ZS et al (2011) Long-term efficacy and safety of tamsulosin hydrochloride for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: data from China. Chin Med J 124:56–60

Tsujimura A, Takao T, Okuda H et al (2010) Survey of lower urinary tract symptoms in patients with benign prostatic hyperplasia and usefulness of tamsulosin hydrochloride. Jpn J Urol Surg 23:301–308

Andersson KE (2004) Antimuscarinics for the treatment of overactive bladder. Lancet Neurol 3:46–53

Szell EA, Yamamoto T, de Groat WC, Somogyi GT (2000) Smooth muscle and parasympathetic nerve terminals in the rat urinary bladder have different subtypes of alpha(1) adrenoceptors. Br J Pharmacol 130:1685–1691

Crawford ED, Wilson SS, McConnell JD et al (2006) Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 175:1422–1427

Kaplan SA, Wein AJ, Staskin DR et al (2008) Urinary retention and post-void residual urine in men: separating truth from tradition. J Urol 180:47–54

Yamaguchi O, Kakizaki H, Homma Y et al (2011) Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms—ASSIST, randomized controlled study. Urology 78:126–133

Kaplan SA, McCammon K, Fincher R et al (2009) Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol 182:2825–2830

Burgio KL, Locher JL, Goode PS et al (1998) Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 280:1995–2000